skip to primary navigationskip to content
 

Dr Mike R Clark FRSB

Dr Mike R Clark, FRSB

Retired (30th September 2014) as Reader in Therapeutic and Molecular Immunology

Antibody Engineering

Antibody Therapy

Therapeutic Immunology

Mike Clark is available for consultancy.


Departments

Department of Pathology:
Retired (30th September 2014) as Reader in Therapeutic and Molecular Immunology

Research Interests

Engineering antibodies for therapeutic applications

Antibody effector functions

Keywords

cytotoxicity ; recombinant antibody ; immunoglobulins ; isotype switching ; B cell receptor (BCR) ; Fc receptors ; engineered Fc ; complement ; diagnostics ; antibody responses ; immunotherapy ; FcgammaRII ; alemtuzumab ; antibody engineering ; campath-1H ; FACS ; lymphoma ; antibody ; B cells ; antibody effector function

Topics

  • autoimmunity
  • autoimmune diseases
  • immunotherapy
  • salmonellosis
  • therapy
  • fetomaternal alloimmune thrombocytopenia

Key Publications

See website listing above for Google Scholar, Research Gate and LinkedIn profiles

Armour KL, Smith CS, Turner CP, Kirton CM, Wilkes AM, Hadley AG, Ghevaert C, Williamson LM, Clark MR. Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets. Eur J. Immunol. 2014 March; 44(3): 905-914

Ghevaert C, Herbert N, Hawkin L, Grehan N, Cookson P, Garner SF, Crisp-Hihn A, Lloyd-Evans P, Evans A, Balan K, Ouwehand WH, Armour KL, Clark MR, Williamson LM. Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood. 2013 July 18;122(3):313-320

Goh YS, Grant AJ, Restif O, McKinley TJ, Armour KL, Clark MR, Mastroeni P. Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology. 2011 May;133(1):74-83

Armour KL, Smith CS, Clark MR. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding. J Immunol Methods. 2010 Mar 31;354(1-2):20-33

Armour KL, Parry-Jones DR, Beharry N, Ballinger JR, Mushens R, Williams RK, Beatty C, Stanworth S, Lloyd-Evans P, Scott M, Clark MR, Peters AM, Williamson LM. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood. 2006 Apr 1;107(7):2619-26.

This is a cartoon model of human IgG1 in which the secondary structure within the model is indicated by both shape and colour. The conserved beta barrel structures making up each immunoglobulin domain along with the beta turns and helical turns at the ends of the beta strands can clearly be identified. If you look carefully you will see that the domain structures for the heavy and light chain V-regions is different from the constant region domains.